The study, published in the journal Nature Communications, includes data for 34,128 COVID-19 patients, of which 8,362 were from the U.S., and the rest were from South Korea and Spain. Researchers compared patient characteristics of the COVID-19 patients to 84,585 people hospitalized with the flu between 2014 and 2019.
They found that COVID-19 patients have more typically been male, younger and had fewer underlying conditions compared to the flu patients. Chronic obstructive pulmonary disease, cardiovascular disease and dementia were all more common among hospitalized flu patients than COVID-19 patients.
Medication use was less common among COVID-19 patients, and hospitalized flu patients used systemic corticosteroids and alpha-blockers more frequently, the study found.
More articles on public health:
25 states where COVID-19 is spreading fastest, slowest: Oct. 6
ER visits for COVID-19 jump in Midwest, Mountain region: 4 CDC findings
COVID-19 survivors, families of deceased pay tribute in remembrance day
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
